Pure Global
NCT06100263

Breast Cancer Resiliency Through Exercise Program (B-REP)

Breast Cancer Resiliency Through Exercise Program (B-REP): Pilot Study
University of Michigan Rogel Cancer Center·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Breast Cancer Female
Drug/Device/Intervention
Individualized exercise program
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
University of Michigan Rogel Cancer Center
Location
Ann Arbor, United States of America
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Oct 01, 2026
Enrollment
60 participants
Primary outcome

Feasibility of the exercise program (Retention),Feasibility of the exercise program (Adherence),Feasibility of the exercise program (fidelity),Satisfaction of program,Affective attitude,Perceived burden,Outcome expectation

Summary

The study will use a cross-sectional study design with a follow-up 2-arm randomized
 controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12),
 and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and a
 health education control among 60 Black breast cancer survivors.

ICD-10 classifications
Malignant neoplasm: Breast, unspecifiedMalignant neoplasm of breastMalignant neoplasm of breastCarcinoma in situ of breast, unspecifiedPersonal history of malignant neoplasm of breast
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06100263
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06100263 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Michigan Rogel Cancer Center and is currently Not yet recruiting. The study focuses on Breast Cancer Female. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.